SCHEMBL94655

SCHEMBL94655

[CH2]c1ccc(NS(=O)(=O)c2ccc(OC)c(OC)c2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.77
HTT P42858 1/20 0.77
SMN1; SMN2 Q16637 1/20 0.77
CA12 O43570 1/20 0.73
CA9 Q16790 1/20 0.73
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
ALOX15 P16050 1/20 0.68
MAPK1 P28482 1/20 0.68
TSHR P16473 3/20 0.67
ALDH1A1 P00352 5/20 0.62
PKM P14618 2/20 0.61
NPSR1 Q6W5P4 1/20 0.61
MAPT P10636 2/20 0.61
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2C19 P33261 1/20 0.60
USP2 O75604 1/20 0.60
HSP90AA1 P07900 1/20 0.60
HSP90AB1 P08238 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8752463 0.84 CA12 (1.00) LMNAHTTSMN1; SMN2CA12CA9
SCHEMBL633327 0.82 CA12 (0.83) LMNAHTTSMN1; SMN2CA12CA9
SCHEMBL5044727 0.82 CA12 (0.73) LMNAHTTSMN1; SMN2CA12CA9
SCHEMBL20522359 0.81 LMNA (0.71) LMNAHTTSMN1; SMN2CA12CA9
SCHEMBL14484127 0.81 TSHR (1.00) LMNAHTTSMN1; SMN2CA12CA9
SCHEMBL17847423 0.80 ALDH1A1 (0.81) LMNAHTTSMN1; SMN2CA12CA9
SCHEMBL6341219 0.80 LMNA (0.79) LMNAHTTSMN1; SMN2CA12CA9
SCHEMBL95815 0.80 GAA (0.73) LMNAHTTSMN1; SMN2MEN1KMT2A
SCHEMBL7573915 0.79 LMNA (0.78) LMNAHTTSMN1; SMN2CA12CA9
SCHEMBL15480533 0.79 MEN1 (0.68) LMNAHTTSMN1; SMN2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB LMNA 3740/4885HTT 4495/4885SMN1; SMN2 3998/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 LMNA 4860/4885HTT 4175/4885SMN1; SMN2 3084/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 LMNA 4860/4885HTT 4175/4885SMN1; SMN2 3084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.